Stockscreener 앱 받기
4.12
8.44%
-0.38
시간 외 거래:
4.12
전일 마감가:
$4.50
열려 있는:
$4.465
하루 거래량:
69,289
Relative Volume:
2.21
시가총액:
$30.10M
수익:
-
순이익/손실:
$-101.87M
주가수익비율:
-2.922
EPS:
-1.41
순현금흐름:
$-83.46M
1주 성능:
-16.26%
1개월 성능:
-28.97%
6개월 성능:
-48.34%
1년 성능:
-49.83%
1일 변동 폭
$3.6201
$4.465
1주일 범위
$3.6201
$4.97
52주 변동 폭
$3.6201
$9.18
Kezar Life Sciences Inc Stock (KZR) Company Profile
명칭
Kezar Life Sciences Inc
전화
650-822-5600
주소
4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
KZR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KZR
Kezar Life Sciences Inc
|
4.12 | 30.10M | 0 | -101.87M | -83.46M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Kezar Life Sciences Inc Stock (KZR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-08-11 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-03-16 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2018-07-16 | 개시 | Jefferies | Buy |
| 2018-07-16 | 개시 | Wells Fargo | Outperform |
| 2018-07-16 | 개시 | William Blair | Outperform |
모두보기
Kezar Life Sciences Inc 주식(KZR)의 최신 뉴스
Kezar Life Sciences stock hits 52-week low at $4.36 - Investing.com
Polymyositis Market Predicted to See Upsurge Through 2034, - openPR.com
Kezar Life Sciences Appoints New Principal Accounting Officer - TipRanks
What is William Blair’s Forecast for KZR Q1 Earnings? - Defense World
KZR stock touches 52-week low at $5.20 amid market challenges By Investing.com - Investing.com South Africa
KZR stock touches 52-week low at $5.20 amid market challenges - Investing.com Australia
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results - BioSpace
Kezar reports positive AIH trial results, financials for 2024 By Investing.com - Investing.com South Africa
Promising Clinical Trial Results and Safety Profile Justify Buy Rating for Kezar Life Sciences - TipRanks
Kezar stock drops on Q4 results, trial data (KZR:NASDAQ) - Seeking Alpha
Kezar Life Sciences Touts Positive Data From Mid-Stage Study For Chronic Liver Disease Drug Candidate - Benzinga
Kezar reports positive AIH trial results, financials for 2024 - Investing.com India
Kezar Life Sciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
KEZAR LIFE SCIENCES Earnings Results: $KZR Reports Quarterly Earnings - Nasdaq
Breakthrough in Autoimmune Hepatitis: Kezar's Drug Achieves 36% Response Rate While Placebo Shows Zero - Stock Titan
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025 - BioSpace
Major Clinical Trial Results: New Autoimmune Hepatitis Treatment Shows PromiseData Reveal Coming - Stock Titan
Amundi Sells 74,019 Shares of Kezar Life Sciences, Inc. (NASDAQ:KZR) - Defense World
KEZAR LIFE SCIENCES INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
How the (KZR) price action is used to our Advantage - news.stocktradersdaily.com
Dermatomyositis Drug Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Treatment Market, Prevalence, Medication, Statistics, Therapies, Companies by DelveInsight - The Globe and Mail
Kezar Life Sciences Inc expected to post a loss of $2.88 a shareEarnings Preview - TradingView
Kezar Life Sciences (KZR) Expected to Announce Quarterly Earnings on Thursday - Defense World
Kezar Life Sciences’ (KZR) Outperform Rating Reiterated at William Blair - Defense World
Kezar stock rating raised to Outperform at William Blair By Investing.com - Investing.com UK
Dermatomyositis Market Generated Opportunities, Future Scope - openPR
(KZR) On The My Stocks Page - Stock Traders Daily
Kezar Life Sciences (KZR) Stock Price, News & Analysis - MarketBeat
Activist investor threatens Peninsula drug maker's merger plans - The Business Journals
Major Clinical Development Update: Stanford Expert Reveals Future of Zetomipzomib in Autoimmune Hepatitis - StockTitan
Objective long/short (KZR) Report - Stock Traders Daily
Kezar Life Sciences files for $400M mixed securities shelf - MSN
Autoimmune Hepatitis Market Growth to Accelerate in Forecast - openPR
Kezar Life Sciences Files $400 Million Mixed Securities Shelf -February 05, 2025 at 05:55 pm EST - Marketscreener.com
Kezar Life Sciences, Inc. (NASDAQ:KZR) Short Interest Update - Defense World
Kezar reports preliminary year-end financial position - Investing.com
Wells Fargo & Company Issues Pessimistic Forecast for Kezar Life Sciences (NASDAQ:KZR) Stock Price - Defense World
HC Wainwright Issues Pessimistic Estimate for KZR Earnings - Defense World
Q4 EPS Estimate for Kezar Life Sciences Decreased by Analyst - MarketBeat
Kezar Life Sciences updates shareholder rights agreement - Investing.com
Kezar Life Sciences (NASDAQ:KZR) Given “Neutral” Rating at HC Wainwright - Defense World
William Blair Has Strong Estimate for KZR FY2024 Earnings - MarketBeat
FY2024 Earnings Estimate for KZR Issued By William Blair - Defense World
Kezar Life Sciences (NASDAQ:KZR) and Summit Therapeutics (NASDAQ:SMMT) Head-To-Head Contrast - Defense World
Wells Fargo & Company Has Lowered Expectations for Kezar Life Sciences (NASDAQ:KZR) Stock Price - Defense World
Kezar struck again with second FDA hold - Clinical Trials Arena
Kezar Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Kezar Life Sciences (NASDAQ:KZR) Receives "Market Perform" Rating from William Blair - MarketBeat
Kezar’s Autoimmune Drug Hit With Second FDA Clinical Hold in as Many Months - BioSpace
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
Kezar Life Sciences Inc (KZR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):